#USA #Halifax #hemostasis #Precision BioLogic #George King

Precision BioLogic Expands Its Horizons

In a significant move to bolster its position in the hemostasis diagnostic market, Precision BioLogic Inc. has announced the acquisition of George King Bio-Medical, a company renowned for its commitment to serving the bleeding disorders community. This strategic acquisition aims to combine the strengths of both organizations to enhance product offerings and customer service.

A Legacy of Service and Innovation

Founded over 50 years ago, George King Bio-Medical has dedicated its efforts to assist individuals affected by bleeding disorders. Paul Empey, President and CEO of Precision BioLogic, explained, "Since its inception, George King Bio-Medical has remained true to its purpose—helping individuals affected by bleeding disorders." He emphasized that both companies share a common goal, which is to support existing customers while identifying new avenues to aid the community further.

Kathryn Blasco, the CEO and President of George King Bio-Medical, echoed Empey's sentiments, stating, "Joining forces with Precision BioLogic enables us to continue our legacy of compassion and innovation. The future looks promising for us and our customers." Under this new partnership, both companies will retain their focus on operations and customer relations while strategizing for long-term growth under the Precision BioLogic umbrella.

Fostering Innovation in Hemostasis Diagnostics

George King Bio-Medical has been pivotal in providing top-quality fresh frozen human plasmas, essential for various clinical laboratory applications. The company's longstanding dedication to product quality and customer service, alongside a robust plasma donor program, has made it a trusted name in the field. With this acquisition, Precision BioLogic will not only enhance its product line but also strengthen its foothold in the diagnostic market nationwide.

Precision BioLogic itself is a prominent name in hemostasis diagnostics, developing, manufacturing, and marketing the CRYOcheck™ line of frozen products used globally for diagnosing coagulation disorders. Notably, the acquisition of Affinity Biologicals in 2018 marked a significant expansion into coagulation-related antibodies, and now this acquisition will elevate its offerings further.

Looking Towards the Future

As the two companies integrate, stakeholders can expect the streamlined development of innovative products and services that meet the needs of medical professionals and patients alike. The synergy created by the merger is anticipated to yield enhanced capabilities for research and development, particularly in the area of bleeding disorders—a crucial area of focus for both organizations.

A Commitment to the Community

The merger aligns with a deeper commitment to the bleeding disorders community, reaffirming both companies’ missions to create effective, reliable diagnostic tools that improve patient outcomes. As stated in the announcement, they will prioritize long-term strategic initiatives that benefit both their customer bases and the healthcare community at large.

In summary, the acquisition of George King Bio-Medical by Precision BioLogic symbolizes a major step towards enhancing diagnostic solutions, showcasing a partnership built on shared values and a mutual dedication to patient care and innovation. The healthcare industry will certainly be watching how this merger unfolds and anticipates exciting advancements in the realm of hemostasis diagnostics as a result.

For more details on these companies' product offerings and their history, visit their respective websites.